Schizophrenia
Conditions
Interventions
Algorithm-guided treatment group: Treatment effectiveness is evaluated by the total score of monthly assessed PANSS. Responder is defined as more than 30% decrease from the baseline. PANSS score (Sta
Sponsors
Department of Neuropsychiatry Keio University School of Medicine
Nippon Medical School Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi Kurumegaoka Hospital, Asai Hospital, Inogashira Hospital, Oizumi Hospital, Komagino Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with schizophrenia diagnosed by DSM-IV. 2. Both in- and out-patients without remission will be recruited. Medication-naive or -free patients will be eligible. If the patients are treated by multiple antipsychotics (polypharmacy), the medication should be switched to one of the atypical antipsychotics (monopharmacy). 3. Patients are not in remission status, not resistant to antipsychotic therapy, and not having any severe complications. 4. Patients agree to participate in the study on a written informed consent form. 5. Patients should be able to receive examination and assessments for pharmaceutical therapy on designated date. 6. Patients with a total score of GAF ranging 11 to 90 and a score of severity in CGI-SCH ranging 3 to 6 are included. Moreover, we select patients with chlorpromazine-conversion dosage of 150mg to 2000mg/ day at baseline.
Exclusion criteria
Exclusion criteria: 1. We exclude patients are in remission status, and showing mild or milder symptoms in all 8 subscales on PANSS. Treatment-resistant cases: We exclude patients receive several antipsychotics (more than chlorpromazine-conversion dosage of 2000mg/ day during at least last 6 months, or taken more than 7 types of antipsychotics), but show a score less than 30 on FACT-SZ (definitely requiring hospitalization level). 2. Patients did not show any sufficient response to more than two kinds of atypical antipsychotics, or patients have intolerability to atypical antipsychotics so far. 3. Patients have severe underlying diseases, such as diabetes, substance dependence at present, serious physical disease, possibility of pregnancy, severe intellectual disorder, and organic brain disorder. 4. Patients show comorbid personality disorders diagnosed by DSM-IV. 5. Patients have high probability of attempting suicide. 6. Patients show an allergic reaction to a medication or have a history of the allergy. 7. Patients do not agree to participate in the study on a written informed consent form. 8. Patients are not able to receive examination and assessments for pharmaceutical therapy on designated date.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive and Negative Syndrome Scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Global Impression Scale-Schizophrenia Version (CGI-SCH) Global Assessment of Functioning (GAF) Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Targeted Inventory on Problem in Schizophrenia (TIP-Sz) and Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz) Short-form 36 v2 Health Survey (SF-36v2) Subjective Wellbeing under Neuroleptic Treatment Scale (SWN-J) | — |
Countries
Japan
Contacts
Public ContactMotoichiro Kato
Keio University Department of Neuropsychiatry, School of Medicine
Outcome results
None listed